UPB Valuation

Upstream Bio Inc

Add to Watchlist

Advanced Chart

23.660

-0.31(-1.293%)1D

UPB Relative Valuation

UPB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, UPB is overvalued; if below, it's undervalued.

Historical Valuation

Upstream Bio Inc (UPB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 23.97 is considered Undervalued compared with the five-year average of -5.21. The fair price of Upstream Bio Inc (UPB) is between 165.96 to 465.60 according to relative valuation methord. Compared to the current price of 23.97 USD , Upstream Bio Inc is Undervalued By 85.56%.

Relative Value

Fair Zone

165.96-465.60

Current Price：23.97

85.56%

Undervalued

-7.58

Trailing

Forward

-5.39

EV/EBITDA

Upstream Bio Inc. (UPB) has a current EV/EBITDA of -5.39. The 5-year average EV/EBITDA is -3.88. The thresholds are as follows: Strongly Undervalued below -11.75, Undervalued between -11.75 and -7.82, Fairly Valued between 0.06 and -7.82, Overvalued between 0.06 and 4.00, and Strongly Overvalued above 4.00. The current Forward EV/EBITDA of -5.39 falls within the Historic Trend Line -Fairly Valued range.

-4.99

EV/EBIT

Upstream Bio Inc. (UPB) has a current EV/EBIT of -4.99. The 5-year average EV/EBIT is -3.47. The thresholds are as follows: Strongly Undervalued below -10.40, Undervalued between -10.40 and -6.94, Fairly Valued between -0.01 and -6.94, Overvalued between -0.01 and 3.45, and Strongly Overvalued above 3.45. The current Forward EV/EBIT of -4.99 falls within the Historic Trend Line -Fairly Valued range.

23.97

Upstream Bio Inc. (UPB) has a current PS of 23.97. The 5-year average PS is 389.46. The thresholds are as follows: Strongly Undervalued below 14.92, Undervalued between 14.92 and 202.19, Fairly Valued between 576.74 and 202.19, Overvalued between 576.74 and 764.01, and Strongly Overvalued above 764.01. The current Forward PS of 23.97 falls within the Undervalued range.

-9.68

P/OCF

Upstream Bio Inc. (UPB) has a current P/OCF of -9.68. The 5-year average P/OCF is -6.80. The thresholds are as follows: Strongly Undervalued below -13.94, Undervalued between -13.94 and -10.37, Fairly Valued between -3.23 and -10.37, Overvalued between -3.23 and 0.35, and Strongly Overvalued above 0.35. The current Forward P/OCF of -9.68 falls within the Historic Trend Line -Fairly Valued range.

-9.75

P/FCF

Upstream Bio Inc. (UPB) has a current P/FCF of -9.75. The 5-year average P/FCF is -12.00. The thresholds are as follows: Strongly Undervalued below -24.79, Undervalued between -24.79 and -18.39, Fairly Valued between -5.61 and -18.39, Overvalued between -5.61 and 0.79, and Strongly Overvalued above 0.79. The current Forward P/FCF of -9.75 falls within the Historic Trend Line -Fairly Valued range.

Upstream Bio Inc (UPB) has a current Price-to-Book (P/B) ratio of 3.15. Compared to its 3-year average P/B ratio of 0.97 , the current P/B ratio is approximately 223.94% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about 223.94% higher. Upstream Bio Inc (UPB) has a Forward Free Cash Flow (FCF) yield of approximately -8.86%. Compared to its 3-year average FCF yield of -11.58%, the current FCF yield is approximately -23.48% lower. Relative to its 5-year average FCF yield of -11.58% , the current FCF yield is about -23.48% lower.

3.15

P/B

Median3y

0.97

Median5y

0.97

-8.86

FCF Yield

Median3y

-11.58

Median5y

-11.58

Competitors Valuation Multiple

The average P/S ratio for UPB's competitors is 18.31, providing a benchmark for relative valuation. Upstream Bio Inc Corp (UPB) exhibits a P/S ratio of 23.97, which is 30.89% above the industry average. Given its robust revenue growth of 12.52%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Dianthus Therapeutics Inc

Enliven Therapeutics Inc

18.50

1.10B

TRVI.O

Trevi Therapeutics Inc

Performance Decomposition

Market capitalization of UPB increased by 9.60% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.63K to -4.94K.

The secondary factor is the Revenue Growth, contributed 12.52%to the performance.

Overall, the performance of UPB in the past 1 year is driven by Margin Expansion. Which is more sustainable.

12.52%

607.00K → 683.00K

Revenue Growth

87.55%

-2.63K → -4.94K

Margin Expansion

-90.47%

-89.19 → -8.50

P/E Change

9.60%